Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eugene Sun

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
The Pediatric Infectious Disease Journal|March 14, 2003
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected childrenXavier Sáez-Llorens, Avyi Violari, Carl O Deetz, et al.
The Journal of Infectious Diseases|February 28, 2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patientsConstance A Benson, Steven G Deeks, Scott C Brun, et al.
The New England Journal of Medicine|September 2, 2022
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant TuberculosisFrancesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov, et al.
The Journal of Antimicrobial Chemotherapy|March 9, 2022
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanidAnna Bateson, Julio Ortiz Canseco, Timothy D McHugh, et al.
The Lancet. Infectious Diseases|May 20, 2024
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialMuge Cevik, Lindsay C Thompson, Caryn Upton, et al.
Bulletin of the World Health Organization|July 29, 2024
Target regimen profiles for tuberculosis treatmentChristian Lienhardt, Kelly E Dooley, Payam Nahid, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
The Pediatric Infectious Disease Journal|March 14, 2003
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected childrenXavier Sáez-Llorens, Avyi Violari, Carl O Deetz, et al.
The Journal of Infectious Diseases|February 28, 2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patientsConstance A Benson, Steven G Deeks, Scott C Brun, et al.
The New England Journal of Medicine|September 2, 2022
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant TuberculosisFrancesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov, et al.
The Journal of Antimicrobial Chemotherapy|March 9, 2022
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanidAnna Bateson, Julio Ortiz Canseco, Timothy D McHugh, et al.
The Lancet. Infectious Diseases|May 20, 2024
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialMuge Cevik, Lindsay C Thompson, Caryn Upton, et al.
Bulletin of the World Health Organization|July 29, 2024
Target regimen profiles for tuberculosis treatmentChristian Lienhardt, Kelly E Dooley, Payam Nahid, et al.
Pageof 4